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A B S T R A C T
It is becoming increasingly clear that the connections between our immune system and the microbiota colonizing
us have a tremendous impact on human health. A number of innate molecular defence mechanisms cooperate to
selectively target unwanted microorganisms at the mucosal surfaces. Amongst others these include the com-
plement system, IgA and the SALSA molecule. The salivary scavenger and agglutinin (SALSA), also known as
deleted in malignant brain tumors 1 (DMBT1), salivary agglutinin (SAG) or gp340 is a multifunctional molecule
with important functions in innate immunity, inflammation and epithelial homeostasis. The SALSA protein is
expressed at most mucosal surfaces, where it is one of the most abundant proteins. In the fetal meconium and
infant intestine it may constitute even up to 10% of the total protein amount. SALSA is found either directly
associated with the epithelial surface or secreted into the lining fluids. In the fluid-phase SALSA interacts with a
number of bacterial and viral organisms, as well as with endogenous ligands, including IgA, lactoferrin, sur-
factant proteins and complement components. While complement has been shown to impact the mucosal en-
vironment, this remains an area of limited research. The multiple interactions of the SALSA molecule provide a
scaffold, where this potent defence system may engage in cooperative microbial clearance together with cor-
responding mucosal host ligands.
With its high abundance, and multiple effects on both host and microbes, the SALSA molecule is a key player
in maintaining the immunological balance at the mucosal surfaces. This is further supported by observations
linking the expression of different SALSA isoforms to the development of chronic inflammatory conditions, such
as Crohn’s disease and ulcerative colitis. This review describes the latest advances in understanding functions of
SALSA and its different isoforms. Recently recognized functions are related to complement activation and reg-
ulation, endothelial development and epithelial homeostasis. In addition, we suggest mechanisms how SALSA
regulates inflammation at the mucosal surfaces.
1. Introduction
In recent years it has become clear that the crosstalk between the
host and the microbiota plays an important role in shaping the human
immune system (Chu et al., 2016; Rooks and Garrett, 2016). The po-
larized epithelial cells and the protein contents of the mucosal secre-
tions play a central role in the interactions with the microbiome (Cone,
2009). A state of balanced immunity is essential for human health. A
weak immune response or a damaged mucosal barrier can lead to in-
fections caused by opportunistic pathogens (Dethlefsen et al., 2007).
However, a mucosal environment favouring an overreactive immune
response may lead to allergies and chronic inflammation, as seen e.g. in
Crohn’s disease (Hugot et al., 2001; Ogura et al., 2001a).
Immunological homeostasis is maintained by the intricate network of
cells and endogenous defence molecules, one of which is the salivary
scavenger and agglutinin (SALSA).
SALSA has widespread functions in innate immunity, inflammation,
epithelial homeostasis and tumor suppression (Kang and Reid, 2003;
Ligtenberg et al., 2007; Madsen et al., 2010; Reichhardt and Meri,
2016). Originally SALSA was identified as a 300–400 kDa salivary
streptococcal agglutinating protein, and named salivary agglutinin
(SAG) (Ericson and Rundegren, 1983). Later, two independent groups
found the protein in other tissues. A 340 kDa glycoprotein was co-
purified with surfactant protein D (SP-D) from bronchoalveolar lavage
fluid and named gp340 (Holmskov et al., 1997). Simultaneously, the
SALSA gene was found to be deleted in several brain tumors, thus
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giving rise to the name ‘deleted in malignant brain tumors 1′ (DMBT1)
(Mollenhauer et al., 1997). Currently, it appears that the various names
describe the same protein expressed in different tissues. To give the
protein a uniform, memorable and functionally related name a common
name for the protein was recently suggested; SALSA (salivary scavenger
and agglutinin) (Reichhardt et al., 2012).
2. The SALSA protein and its isoforms
The gene encoding the SALSA protein, the DMBT1 gene, contains 54
exons and spans 80 kb of the human genome. The expressed gene en-
codes 13 scavenger receptor cysteine-rich (SRCR) domains linked by
short proline-rich segments named SRCR interspersed domains (SIDs).
The SRCR domains are followed by two “C1r/C1s, urchin embryonic
growth factor and bone morphogenetic protein-1” (CUB) domains sur-
rounding the 14th SRCR domain, and finally, a zona pellucida (ZP)
domain in the C-terminus (Fig. 1) (Holmskov et al., 1999; Mollenhauer
et al., 1999). Evolutionarily, the 109–110 amino acid SRCR domains are
highly conserved motifs that have been described in both mammals,
vertebrates and even invertebrates such as blue-green algae and
sponges (Mollenhauer et al., 1999; Sarrias et al., 2004; Wheeler et al.,
2008). The first 13 SRCR repeats of SALSA are very homologous having
90–100% identity at the nucleotide level (SRCR3/7 and SRCR10/11
being 100% identical). The repeats therefore form an obvious target for
alternative splicing, which leads to the expression of different SALSA
isoforms, each with different numbers of SRCR and SID domains
(Holmskov et al., 1999; Mollenhauer et al., 1999, 2002b). Recent stu-
dies identified two distinct areas of the DMBT1 gene prone to internal
copy number variation (CNV) (Polley et al., 2015). In this type of ge-
netic variation only part of a gene (e.g. the amount of SRCR-SID re-
peats) varies in number between individuals. Specifically for DBMT1
two copy number variants exist, CNV1 (covering 4 SRCR domains) and
CNV2 (covering an individual SRCR domain) (Polley et al., 2015). Due
to the high homology between the individual SRCR domains a slight
uncertainty of the specific localization of CNV1 exists. Thus, the CNV1
variation may lead to either addition or deletion of the SRCR3-6 or the
SRCR4-7 regions (Mollenhauer et al., 2002c; Polley et al., 2015). CNV2
may result in 0–5 copies of SRCR10. Thus the expressed proteins are
expected to vary from 7 up to 20 N-terminal SRCR domains (Fig. 1)
(Polley et al., 2015, 2016). Several other deletions and single nucleotide
polymorphisms (SNPs) have been described in the DBMT1 gene
(Diegelmann et al., 2013; Sasaki et al., 2002). Variation in the numbers
of expressed repeats has been found in up to 28% of normal individuals
(Mollenhauer et al., 2000). At the protein level Western blotting has
verified the variation in the sizes of SALSA proteins from different in-
dividuals. Moreover, the protein size appears to vary in different tissue
compartments of the same individual, as well (Eriksson et al., 2007;
Loimaranta et al., 2005; Reichhardt et al., 2014). However, it has been
estimated that 25–45% of the molecular mass of the SALSA protein
arises from glycosylation, which may explain part of the observed
variation (Ericson and Rundegren, 1983; Holmskov et al., 1999). The
sugar moieties on SALSA include e.g. N-glycans,sialylated Galβ1-
3GalNAc and lactosamine structures (Eriksson et al., 2007; Hartshorn
et al., 2006; Oho et al., 1998). Interestingly, both ABO blood group and
Lewis antigens are found differentially expressed on SALSA depending
on the secretor (Se(+/−)) status (+/− expression of the α1-2fucosyl-
transferase). ABO and Lewis antigens b and y (Leb and Ley) were found
on SALSA from Se(+) individuals. These sugar moieties were not found
on SALSA from Se(−) individuals. In contrast, SALSA from the Se(−)
individuals contained Lewis antigens a and x (Lea and Lex) (Eriksson
et al., 2007; Ligtenberg et al., 2000). A comparison of SALSA expressed
in different secretions revealed additional variations in glycosylation
(Eriksson et al., 2007; Schulz et al., 2002). Thus, the observed varia-
tions between the SALSA isoforms may both originate from differences
in the number of SRCR/SID domains as well as differences in glycosy-
lation (Eriksson et al., 2007; Loimaranta et al., 2005; Prakobphol et al.,
2005; Reichhardt et al., 2014; Schulz et al., 2002).
3. Expression of SALSA
The SALSA molecule was originally isolated from mucosal secre-
tions. Thus, most research has focused on its expression at various
mucosal surfaces. However, recently several reports have shown ex-
pression of the protein also in non-epithelial tissues (see below). A full
list of tissues with described expression of SALSA is shown in Table 1.
At the mucosal surfaces, SALSA is found both in the epithelium and
Fig. 1. SALSA structure.
Displayed is a selection of SALSA isoforms as iden-
tified by cDNA sequencing and population genetic
copy number variation (CNV) studies. The isoforms
are drawn to scale with predicted lengths calculated
on the basis of structurally similar domains of
chicken ZP3 (ZP domain), rat MASP-2 (CUB domain
arrangement), and human CD5 and CD6 (SRCR do-
mains) (Chappell et al., 2015; Feinberg et al., 2003;
Han et al., 2010; Rodamilans et al., 2007)). (A) Ca-
nonical full length SALSA, as originally identified.
Domains 10–11 are up to 100% identical at the nu-
cleotide level. (B) Shortest version of the SALSA
protein as identified by CNV analysis. (C) Deletion
variant associated with Crohn’s disease, also referred
to as dmbt147 (Mollenhauer et al., 1999). (D) Longest
proposed variant with duplication at the CNV1 and 5
repeats of SRCR10 at CNV2, here named 10, 11, and
in accordance with the canonical full length model
followed by additional identical repeats; 11a, 11b
and 11c. ZP: zone pellucida, CUB: C1r/C1s, urchin
embryonic growth factor and bone morphogenetic
protein-1, SRCR: scavenger receptor cysteine-rich,
SID: SRCR interspersed domain, ST-rich linker:
serine-threonine rich linker, P-rich linker: proline-
rich linker.
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in the secretory glands of the lungs, trachea, oral cavity, esophagus,
stomach, small and large intestine, pancreas, gallbladder, mammary
glands, vagina and cervix (Braidotti et al., 2004; Holmskov et al., 1999;
Kang et al., 2002; Mollenhauer et al., 1997, 2000, 2001; Stoddard et al.,
2007; Thornton et al., 2001). Both glandular and epithelial cells have
been shown to produce the protein and secrete it into the surrounding
fluids, such as saliva, tear fluid, respiratory mucosal secretions, pan-
creatic juice, breast milk and amniotic fluid (Ericson and Rundegren,
1983, Gronborg et al., 2004; Holmskov et al., 1997; Reichhardt et al.,
2014; Ronellenfitsch et al., 2012; Schulz et al., 2002; Thornton et al.,
2001).
In recent studies SALSA was estimated to make up 10% of the total
protein content in meconium and in saliva of young children
(< 3 years). This makes SALSA one of the most abundant proteins on
these mucosal surfaces in early life, highlighting its important and ap-
parently protective role at this stage (Reichhardt et al., 2014; Sonesson
et al., 2011).
4. Binding of SALSA to microbes
Although the human body is virtually sterile at birth, it is im-
mediately colonized by a multitude of microorganisms from the sur-
rounding environment, and in particular from the maternal vaginal
flora (Levy, 2007; Tlaskalova-Hogenova et al., 2004). Indeed, some
studies claim that bacterial colonization may occur already inside the
amniotic cavity (Bearfield et al., 2002; Jimenez et al., 2008). While we
exist in a mutualistic relationship with most of the microbial colonizers,
a strict regulation of the antimicrobial response is essential for the
development of the microbiota in early life.
SALSA has been shown to bind and agglutinate a broad spectrum of
bacteria, including Actinomyces odontolyticus, Helicobacter pylori,
Salmonella enterica serovar Typhimurium, Staphylococcus aureus,
Bifidobacterium lactis, a number of lactobacillus strains, and as well
many types of streptococci (Table 2) (Haukioja et al., 2008; Jumblatt
et al., 2006; Loimaranta et al., 2005; Prakobphol et al., 2000; Rosenstiel
et al., 2007). Also the influenza A virus (IAV) and human im-
munodeficiency virus type 1 (HIV-1) have been shown to bind SALSA
(Hartshorn et al., 2003; Nagashunmugam et al., 1998). Studies with
SALSA orthologues from other mammalian species have identified ad-
ditional binding partners, such as Haemophilus influenzae, Klebsiella
oxytoca and Streptococcus pneumoniae (Madsen et al., 2003).
A main effector function of the SALSA molecule is simply microbial
agglutination. This is an efficient mechanism for inhibiting the micro-
bial colonization as has been shown for S. enterica, IAV and HIV-I
(Hartshorn et al., 2003; Nagashunmugam et al., 1998; Rosenstiel et al.,
2007; Wu et al., 2003). However, the specific ability of the protein to
Table 1
SALSA expression in human tissues and secretions.
Tissue Location Evidence
Adult
Bone marrow Not known RT-PCR (Mollenhauer et al., 2000)
Brain Purkinje cells, granular layer, some astrocytes and neuronal cells, perivascular
macrophages
RT-PCR, IHC (Holmskov et al., 1999; Mollenhauer et al., 1997,
2000)
Colon Epithelium IHC (Mollenhauer et al., 2001)
Duodenum Enterocytes, crypt cells, Brunner’s glands IHC (Mollenhauer et al., 2001)
Esophagus Epithelium, mucus glands IHC (Mollenhauer et al., 2001, 2002a)
Eye Acinar cells of lacrimal glands, conjunctival epithelium RT-PCR, IHC (Jumblatt et al., 2006)
Female genital tract Epithelium IHC (Stoddard et al., 2007)
Gallbladder Epithelium IHC (Mollenhauer et al., 2002a)
Heart tissue Endothelium, myocytes RT-PCR (Muller et al., 2009)
Kidney Collecting duct epithelium RT-PCR (Holmskov et al., 1999)
Liver Hepatocytes IHC (Mollenhauer et al., 2001)
Lung Epithelium, macrophages RT-PCR, IHC (Holmskov et al., 1999; Mollenhauer et al., 1997)
Lymph node Not known RT-PCR (Mollenhauer et al., 2000)
Mammary gland Epithelium RT-PCR, IHC (Braidotti et al., 2004; Holmskov et al., 1999)
Pancreas Langerhans islets, exocrine acinar cells, pancreatic ducts RT-PCR, IHC (Holmskov et al., 1999; Mollenhauer et al., 2001)
Prostate Not known RT-PCR (Holmskov et al., 1999)
Salivary glands Epithelium RT-PCR, IHC (Holmskov et al., 1999; Mollenhauer et al., 2001)
Sinus Serous glands RT-PCR, IHC (Kim et al., 2007)
Skin Epithelium IHC (Mollenhauer et al., 2002a)
Small intestine Epithelium RT-PCR, NB, IHC (Holmskov et al., 1999; Mollenhauer et al.,
1997)
Spleen Not known RT.PCR (Mollenhauer et al., 2000)
Stomach Epithelium, gastric glands RT-PCR, IHC (Holmskov et al., 1999; Mollenhauer et al., 2001,
2002a)
Testis Not known RT-PCR (Holmskov et al., 1999)
Thymus Not known RT-PCR (Mollenhauer et al., 2000)
Tonsils Epithelium IHC (Mollenhauer et al., 2002a)
Trachea Serous cells RT-PCR, IHC (Holmskov et al., 1999; Thornton et al., 2001)
Uterus Not known RT-PCR (Holmskov et al., 1999)
Fetus
Intestine Epithelium IHC (Mollenhauer et al., 2000)
Kidney Collecting duct epithelium IHC (Mollenhauer et al., 2000)
Lung Not known NB (Mollenhauer et al., 1997)
Skin Epithelium, epidermis IHC (Mollenhauer et al., 2000, 2002a)
Secretions
Bronchoalveolar lavage WB (Holmskov et al., 1997)
Pancreatic juice MS (Gronborg et al., 2004)
Respiratory mucosal secretions WB (Thornton et al., 2001)
Saliva MS (Ligtenberg et al., 2001)
Sinus mucosa WB (Kim et al., 2007)
Tear fluid MS (Schulz et al., 2002)
IHC, Immunohistochemistry; NB, Northern blotting; WB, Western blotting; RT-PCR, Reverse transcriptase polymerase chain reaction; MS, Mass spectrometry.
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bind various microbes is dependent on the physical location of the
protein. S. mutans is the causative agent of dental caries, while viridans-
group streptococci are part of the commensal oral flora. The binding of
SALSA to streptococci is mediated through interactions with the
streptococcal surface protein antigen I/II (AgI/II) (Brady et al., 1992;
Demuth et al., 1990). Different parts of the AgI/II molecule are engaged
in the interactions with either fluid-phase or surface-bound host mo-
lecules. These protein domains vary between streptococcal species
(Jenkinson and Demuth, 1997). In the fluid phase SALSA was shown to
agglutinate certain streptococcal strains. However, when SALSA was
directly associated with a surface, such as the hydroxyapatite of the
teeth, SALSA no longer bound these microbes (Loimaranta et al., 2005).
In contrast, other streptococcal strains exclusively adhered to the sur-
face bound protein (Loimaranta et al., 2005). This binding specificity
was found to vary even for strains within the same streptococcal spe-
cies. The binding may be linked to the alternate binding ability of AgI/
II. Fluid-phase SALSA was also shown to agglutinate and clear group B
streptococci. However, group B streptococci were able colonize the
human salivary pellicle utilizing pili in a solid-phase specific binding to
SALSA on the tooth surface (Brittan and Nobbs, 2015). Thus, the
characteristics and localization of the SALSA-microbe binding sites
strongly affect the outcome for the microbe, and determine if it will
colonize the human surface or if it will be agglutinated in the fluid
phase and excreted.
Previous work investigating the bacterial binding properties of
SALSA identified a peptide sequence within each SRCR domain re-
sponsible for the agglutination of most bacterial ligands. This peptide
sequence (RVEVLYxxxSW), designated SRCR-peptide 2 (SRCRP2), is
found in an outer surface loop that is homologous in all the SRCR do-
mains (Bikker et al., 2002, 2004; Leito et al., 2008). However, con-
trasting data arose from a recent study utilizing recombinant forms of
SRCR domains 1–3 in binding assays with several AgI/II protein
homologs (Purushotham and Deivanayagam, 2014). The authors found
that the binding of an individual SALSA SRCR domain to AgI/II re-
quired a minimum of two distinct binding sites, without an overlap with
the SRCRP2. Most binding interactions with SALSA appear to be cal-
cium dependent (Loimaranta et al., 2005; Madsen et al., 2003;
Reichhardt et al., 2012). The addition of calcium to the recombinant
SRCR domains 1–3 induced a conformational change. This structural
change was, however, stronger for the surface-immobilized SRCR do-
mains than to the soluble domains (Purushotham and Deivanayagam,
2014). The differential binding of various microbial ligands could thus
be a product of different protein conformations induced by calcium.
The ability of SALSA to agglutinate bacteria is an important innate
defence mechanism. However, the ability of certain microbes to bind
the surface-immobilized SALSA can also have detrimental effects on
human health. In a study of dental caries certain SALSA-phenotypes
correlated with both adhesion of S. mutans and the development of
dental caries (Jonasson et al., 2007). There was, however, a difference
in this correlation, when comparing different SALSA isoforms. For HIV-
infection, vaginal transmission of the virus is often much more suc-
cessful than oral transmission (Yu and Vajdy, 2010). In the mouth the
secreted salivary SALSA protein was found to interfere with oral
transmission of the HIV-1 particles. However, SALSA expressed on the
vaginal epithelium was found to aggregate the virus close to the epi-
thelial surface. Thereby, SALSA had an enhancing effect on the in-
fectivity of the virus (Stoddard et al., 2007). In addition, both anti-
bodies and peptides that block the SALSA–HIV-1 interactions also
inhibit HIV-1 transcytosis from the apical to the basolateral epithelial
cell layer (Stoddard et al., 2009). These findings suggest that some
microbes have evolved mechanisms to exploit SALSA to infect the
human body.
Another example of an immune-compromising effect of SALSA is its
interaction with the influenza A virus (IAV). Fluid-phase SALSA ag-
glutinates IAV particles and inhibits their infectivity (Hartshorn et al.,
2003). IAV binds specifically to sialic acid carbohydrate ligands in the
SID-regions of SALSA. SALSA thus functions as a γ-inhibitor preventing
IAV hemagglutinin from binding cellular receptors on the human host
(Hartshorn et al., 2006; White et al., 2009). While the anti-IAV activity
of SALSA is mainly carried out in concert with other endogenous mo-
lecules, such as SP-D, certain glycoforms of SALSA were shown to bind
strongly to the carbohydrate recognition domain of SP-D and thus an-
tagonize the anti-viral effect (Hartshorn et al., 2006). The specific
binding properties of the SALSA molecule, which may both vary with
localization of the protein as well as between the individual iso- and
glycoforms, can greatly affect which microbes are capable of colonizing
Table 2
Endogenous and microbial ligands of SALSA. The listed ligands have been found to bind either human SALSA, the murine-ortholog of SALSA or the recombinantly expressed bacterial
binding peptide, SRCRP2.
Endogenous ligand Suggested functional relevance
C1q Complement regulation (Boackle et al., 1993)
MBL Complement regulation (Reichhardt et al., 2012)
Ficolins Complement regulation (Reichhardt et al., 2012)
SpD Microbial agglutination (Holmskov et al., 1997)
SpA Microbial agglutination (Tino and Wright, 1999)
IgA Microbial agglutination (Ericson and Rundegren, 1983)
Lactoferrin Mucosal surfaces, bacterial binding (Mitoma et al., 2001)
DNA Inflammation (End et al., 2009)
Heparan sulfate Inflammation (End et al., 2009)
Trefoil factors Tissue homeostasis (Thim and Mortz, 2000)
MUC5B Microbial agglutination (Wickstrom et al., 2000)
Erythrocytes Aggregation (Muller et al., 2009)
Platelets Aggregation (Muller et al., 2009)
EGF, Delta-like 4, Vascular endothelial growth factor Endothelial cell adhesion, proliferation and reparative angiogenesis (Muller et al., 2012)
Galectin-3 Cell differentiation (Muller et al., 2012; Roldan and Marini, 2013; Rossez et al., 2011)
Fibrin/Fibrinogen Not known (Muller et al., 2009)
Fibronectin Not known (Reichhardt et al., 2016)
Microbe Specific strains
Streptococcus: S. pyogenes, S. agalactiae, S. pneumonia, S. mutans, S. mitis, S. oralis, S. salivarius, S. gordoni, S. crista, S. parasanguis, S. vestibularis, S. intermedius, S. anginosus, S.
suis (Gunput et al., 2015; Loimaranta et al., 2005; Madsen et al., 2003; Prakobphol et al., 2000)
Lactobacillus: L. rhamnosus, L. casei, L.reuteri, L. lactis (Haukioja et al., 2008)
Other bacteria: Staphylococcus aureus, Bifidobacterium, Actinomyces, Salmonella enterica serovar Typhimurium, Helicobacter pylori, Haemophilus influenzae, Klebsiella oxytoca
(Haukioja et al., 2008; Jumblatt et al., 2006; Loimaranta et al., 2005; Madsen et al., 2003; Prakobphol et al., 2000; Rosenstiel et al., 2007)
Viruses: HIV, IAV (Hartshorn et al., 2003, Nagashunmugam et al., 1998)
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a particular surface or not. The variations in SALSA may therefore have
implications for the composition of the local microbiome and the state
of the inflammatory environment. Consequently, this may affect the
tight regulation of the immunological balance at the mucosal surfaces.
5. Endogenous ligands of SALSA
A number of interactions have been described between the SALSA
protein and other endogenous molecules. The binding partners include
secretory IgA, surfactant proteins A (SP-A) and D (SP-D), lactoferrin,
fibrin/fibrinogen, fibronectin, trefoil factors, mucin-5B, galectin-3,
epidermal growth factor (EGF), vascular endothelial growth factor
(VEGF), C1q, mannose binding lectin (MBL) and ficolins 1–3 (see
Table 2 for a complete list) (Boackle et al., 1993; Holmskov et al., 1997;
Madsen et al., 2013; Muller et al., 2009, 2012; Oho et al., 2004;
Reichhardt et al., 2012, 2016; Rundegren and Arnold, 1987; Thim and
Mortz, 2000; Thornton et al., 2001; Tino and Wright, 1999). In body
secretions SALSA has been found to oligomerize into larger complexes,
either alone or through interactions with the above mentioned ligands
(Crouch, 2000; Madsen et al., 2010; Oho et al., 1998; Young et al.,
1997). Most interactions appear to be calcium-dependent, and indeed a
recent work demonstrated that the SRCR domains of SALSA have an
increased structural stability in the presence of increasing calcium
concentrations (Purushotham and Deivanayagam, 2014). Calcium is
expected to be important for ligand interactions of both CUB and SRCR
domains. Both CUB and SRCR domains may thus affect SALSA-ligand
interactions as well as SALSA polymerization (Andersen and Moestrup,
2014).
5.1. SALSA and complement
In recent years several studies have identified SALSA as a novel
regulator of the complement system (Boackle et al., 1993; Gunput et al.,
2015; Leito et al., 2011; Reichhardt et al., 2012). The complement
system consists of more than 40 soluble and surface-bound proteins
with established immunological functions including anti-microbial de-
fence, immune regulation, clearance of apoptotic cells, immune com-
plexes and debris, as well as cell signalling (Dunkelberger and Song,
2010; Freeley et al., 2016; Meri and Jarva, 1998; Ricklin et al., 2010).
Targeting of foreign and altered self-structures by the complement
system leads to deposition of opsonins (e.g. C1q, C3b, iC3b and C4b),
the complement membrane attack complex (MAC) and the production
of potent pro-inflammatory mediators, such as C3a and C5a
(Markiewski et al., 2007; van Lookeren Campagne et al., 2007; Walport,
2001; Wetsel, 1995). The complement system is activated by three
distinct pathways; the classical, the lectin and the alternative pathways.
The classical and lectin pathways are activated by binding of C1q
(classical pathway) or mannose binding lectin (MBL), ficolins or the
heteromeric complex CL-K1/CL-L1 (lectin pathway) to their respective
targets (Henriksen et al., 2013; Wallis et al., 2010). Target-binding by
these molecules induces conformational changes and proteolytic clea-
vages that activate the associated serine proteases, C1r/s and MBL-as-
sociated serine proteases 1 and 2 (MASP1 and MASP2), for the classical
and the lectin pathways, respectively (Bally et al., 2009; Phillips et al.,
2009). Activated C1s or MASP2 subsequently cleave the next comple-
ment components C4 and C2 to form the classical/lectin pathway C3
convertase C4b2a. This in turn will activate C3 and C5 to generate C3b
and C5b as well as the fluid-phase components C3a and C5a (Wallis
et al., 2010). In the alternative pathway C3 is activated by the C3bBb
enzyme, where Bb is the product of factor D mediated cleavage of factor
B. C3b can deposit covalently to surfaces, and the alternative pathway
can amplify activation on targets recognized as non-self (Meri, 2016).
Complement is mainly a system that operates in blood. However,
during certain conditions blood leaks onto the mucosal surfaces, such as
in the oral cavity or the airways (Boackle, 1991; Persson et al., 1991).
This happens in everyday situations such as tooth brushing, but can be
particularly observed during inflammation of the mucosa, as observed
in the oral cavity with gingivitis and periodontal disease, or in the
airways with cystic fibrosis (Boackle, 1991; Hoek et al., 2002; Negut
et al., 2007; Norkina et al., 2004; Sass et al., 2015). Very little is known
about how complement is regulated in this non-parenteral environ-
ment. When complement proteins enter the mucosa they may interact
with endogenous molecules such as SALSA.
SALSA binds directly to C1q, MBL and all three ficolins (Boackle
et al., 1993; Gunput et al., 2015; Leito et al., 2011; Reichhardt et al.,
2012). Surface-attached SALSA was shown to activate the complement
system both through the interaction with C1q and MBL. In addition,
residual activation observed in ELISA-based assays was suggested to
arise from the interactions with the ficolins (Boackle et al., 1993;
Gunput et al., 2015; Leito et al., 2011; Reichhardt et al., 2012). How-
ever, as observed for microbial agglutination, activation of complement
also appears to depend on the specific localization of SALSA. Thus,
when SALSA was free in serum, it was shown to inhibit complement
activation (Gunput et al., 2016; Reichhardt et al., 2012). The dual ef-
fects of SALSA on the complement system may appear contradictory at
first glance. However, a likely explanation could be that SALSA, when
bound to a surface, may direct complement activation against certain
targets, like microbes. In contrast, SALSA binding to complement
components in the fluid phase may prevent their binding to microbial
targets and thus inhibit complement activation. SALSA may therefore
be involved in an important mechanism underlying immunological
discrimination of targets to be cleared vs. structures to be tolerated.
Interestingly, the interaction with MBL appears to be dependent on the
secretor status, i.e. the presence of distinct carbohydrate moieties on
SALSA such as ABO and Lewis antigens (Gunput et al., 2015). In con-
trast, the lectin pathway inhibition of fluid phase SALSA does not seem
to depend on secretor status. (Gunput et al., 2016). This presents a
mechanism for individual differences in the ability to utilize SALSA for
complement regulation. In the future, it will be interesting to in-
vestigate this particular mechanism in relation to both infections and
inflammatory conditions.
5.2. SALSA and IgA
SALSA and IgA are patrolling the mucosal surfaces together. Both
are provided in high amounts to infants, e.g. through breast milk
(Ronellenfitsch et al., 2012). In saliva the native form of SALSA is found
directly complexed with dimeric IgA (Ericson and Rundegren, 1983).
Together, the two proteins were shown to mediate the agglutination of
S. mutans, although the main binding ability was ascribed to SALSA
(Ligtenberg et al., 2004; Oho et al., 1998; Rundegren and Arnold,
1987). Studies identified the previously discussed SRCRP2 peptide of
SALSA as the binding site for both IgA and S. mutans (Ligtenberg et al.,
2004). However, these interactions did not appear to be competing.
Rather, the complexing of SALSA and IgA was shown to enhance the
bacterial agglutination (Rundegren and Arnold, 1987). Interestingly,
IgA has also been shown to interact with MBL and induce complement
activation (Roos et al., 2001). Together, SALSA, IgA and MBL could
form a potent anti-microbial network. The effect of SALSA on ficolins
and C1q could lead to a redundancy in this system, ensuring effective
clearance even in the case of MBL deficiency.
5.3. SALSA and surfactant proteins
SALSA also binds directly to the two surfactant protein lectins SP-A
and SP-D (Holmskov et al., 1997; Tino and Wright, 1999). They both
belong to the protein family of collectins, i.e. have a collagen-like tail
and a carbohydrate binding globular domain. The lectin domains of SP-
D and SP-A bind SALSA in a calcium-dependent manner (Holmskov
et al., 1997; Tino and Wright, 1999). Both SP-D and SP-A are molecules
expressed at the mucosal surfaces with known microbial agglutinating
functions (Hakansson and Reid, 2000; Holmskov et al., 2003). In vitro,
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binding of SP-D to influenza A (IAV) was shown to induce a strong
respiratory burst response in neutrophils (White et al., 2005). Inter-
estingly, the interaction of SALSA with SP-D resulted in a reduced re-
sponse. This suggests that SALSA may function to limit a potentially
harmful respiratory burst response, while ensuring an increased clear-
ance of the infecting virus (Madsen et al., 2010; White et al., 2005).
This could thus be an additional mechanism of SALSA to assist micro-
bial clearance while hindering an exacerbated immunological response.
5.4. SALSA and lactoferrin
Lactoferrin is a protein found at the mucosal surfaces and in se-
cretions, such as breast milk and tear fluid. Like SALSA, lactoferrin has
been shown to influence cell differentiation, antimicrobial defence and
inflammation (Ward et al., 2005). Lactoferrin modulates the im-
munological environment by chelating iron, an essential nutrient for
most microorganisms. In addition, proteolysis of lactoferrin produces
smaller peptides with direct antimicrobial effects (Groenink et al.,
1999; Singh et al., 2002). Both the human and the bovine forms of
lactoferrin have been found to interact with SALSA, and again the in-
teraction site was suggested to be the SRCRP2 peptide (End et al., 2005;
Ligtenberg et al., 2004; Mitoma et al., 2001). However, whereas the
interaction between SALSA and IgA increased bacterial agglutination,
the binding of SALSA to lactoferrin was shown to inhibit this effect
(Ligtenberg et al., 2004; Mitoma et al., 2001).
5.5. Multiple ligand interactions
A key to understanding the function of SALSA is not only its mul-
tiple interactions, but more importantly: which of these would occur at
the same time. The described complexing of SALSA and IgA and the
potential co-operative effect it has on streptococcal agglutination sug-
gests that SALSA binds both IgA and the bacteria simultaneously
(Ericson and Rundegren, 1983; Ligtenberg et al., 2004; Oho et al., 1998;
Rundegren and Arnold, 1987). As SALSA apparently can polymerize, it
may generate large protein complexes with multiple bacterial binding
sites (Crouch, 2000). This could lead to efficient bacterial agglutination.
In addition, the interactions with complement proteins would suggest
that microbe-bound SALSA can target complement activation to the
microbial surfaces and thus assist microbial killing (Boackle et al.,
1993; Gunput et al., 2015; Leito et al., 2011; Reichhardt et al., 2012). If
the mucosal barrier is breached, SALSA could both target complement
attack to the microbial surface, and function as a bridging molecule to
attract other agglutinating proteins such as IgA and surfactant proteins.
These, in turn could limit the mobility of the microbes and thus reduce
their infectivity (Fig. 2). This form of bridging and multi-complexing
function would provide an evolutionary explanation for the multiple
copies of the highly homologues SRCR domains that SALSA contain.
They may simply be essential for multiple interactions.
6. SALSA in disease
The interactions of SALSA with the intestinal microflora and innate
immune components makes SALSA an obvious candidate to influence
the disease development and prognosis of inflammatory mucosal dis-
eases. Indeed, increased SALSA expression has been observed in the
epithelium of several chronic inflammatory conditions, including
chronic sinusitis, cystic fibrosis in addition to Crohn’s disease (CD) and
ulcerative colitis (UC) (Hamm et al., 2010; Kim et al., 2007; Madsen
et al., 2013; Renner et al., 2007; Rosenstiel et al., 2007). The stimula-
tion of epithelial cell lines with phorbol 12-myristate 13-acetate and
dextran sodium sulphate, two compounds used to mimic pathological
inflammatory conditions, as well as direct induction by pro-in-
flammatory stimuli such as lipopolysaccharide (LPS), muramyl dipep-
tide and tumor necrosis factor α (TNF-α) led to enhanced expression of
SALSA in the affected tissue (Kang et al., 2002; Renner et al., 2007;
Rosenstiel et al., 2007). These findings show that an increased expres-
sion of SALSA is part of the normal inflammatory response of the epi-
thelium.
6.1. SALSA in inflammatory bowel disease
Inflammatory bowel disease (IBD) constitutes the conditions CD and
UC. Both diseases are characterized by a chronic inflammation of the
intestinal mucosa, although the locations and types of inflammation are
different. A steep increase in the incidence of IBD means that up to 1 in
180 adults in the Western world are now affected (Molodecky et al.,
2012). The etiologies of both CD and UC are currently unknown. Ac-
cumulating data suggests that a dysregulation of the immune response
towards the colonizing microflora in genetically susceptible individuals
is involved (Garcia Rodriguez et al., 2006; Porter et al., 2008; Van
Limbergen et al., 2009).
The cytokines IL-22 and IL-27 have been found to exacerbate mu-
cosal inflammation (Diegelmann et al., 2012; Sugimoto et al., 2008;
Zenewicz et al., 2008). IL-22 stimulation leads to increased production
of IL-6 and IL-8 in the gastrointestinal mucosa, and IL-22 production
has been found to be increased in CD (Andoh et al., 2005; Brand et al.,
2006). Likewise, both IL-27 and its receptor are upregulated in inflamed
intestinal tissue and CD (Diegelmann et al., 2012). IL-22 and IL-27 were
shown to induce SALSA expression through STAT3, NFκB, ATF-2 and
CREB1 signalling, and the enhanced expression of IL-22 and IL-27 in the
inflamed mucosa correlated directly to increased SALSA levels
(Diegelmann et al., 2012; Fukui et al., 2011; Xu et al., 2015).
Nucleotide-binding oligomerization domain 2 (NOD2) is involved in
the intracellular recognition of microbial targets and is one of the major
CD susceptibility genes (Ahmad et al., 2002; Hugot et al., 2001; Ogura
et al., 2001b). Together with TLR4 activation, stimulation of NOD2 was
also shown to directly induce SALSA expression (Rosenstiel et al.,
2007). As for IL-22, this was mediated through NFκB signaling. While
inflammatory and microbial agents induce SALSA expression by the
epithelium, it was shown that SALSA itself appears to function as part of
a negative feedback mechanism. In a study of epithelial response to S.
enterica-derived LPS and muramyl dipeptide it was found that the
presence of SALSA inhibited IL-8 secretion and TLR4 activation
(Rosenstiel et al., 2007). A similar effect was described for cells of the
myeloid cell line THP-1 (Rosenstiel et al., 2007). Although SALSA is
secreted as part of an inflammatory response by epithelial and other
mucosal secretory cells, the function of SALSA may be important for
controlling inflammation. SALSA assists the immunological clearance at
the mucosal surfaces without provoking an exacerbated inflammation.
In the case of chronic inflammation, it is therefore not surprising that
genetic data suggests that insufficient SALSA function may be linked to
disease.
A genetic deletion variant of the above described CNV1 has been
directly associated with CD (Renner et al., 2007). The study showed by
CNV association studies that the expression of a SALSA isoform lacking
the SRCR4-7 region (dmbt147−/−) made individuals susceptible to CD
with an odd’s ratio of 1.75. The lack of these SRCR domains could lead
to weaker bacterial binding and bacterial clearance, which conse-
quently would shift the anti-bacterial response towards increased mu-
cosal inflammation. This study was performed on an Italian cohort and
suggested that SALSA could be used as a clinical marker for the disease
(Polley et al., 2016; Renner et al., 2007). In contrast, however, a recent
study analysing three northern European cohorts was unable to confirm
the association between CNV1 deletion and CD (Polley et al., 2016). In
addition to the dmbt47−/− isoform, another study identified a single
nucleotide polymorphism (SNP) (rs2981804) that was also found to
correlate with CD (Diegelmann et al., 2013). This mutation is in a non-
coding part of the DMBT1 gene, but alters the binding of the tran-
scription factors CREB1 and ATF-2, thus leading to decreased SALSA
expression. So although it currently remains unclear which exact mu-
tations are responsible for the involvement in chronic inflammation, it
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appears that a link exists between a diminished SALSA function and
predisposition to CD. Interestingly, the development of paediatric IBD
has also been linked to impaired function of the lectin and classical
pathways of complement. Disease was associated with a higher fre-
quency of the MBL2 gene and two separate C4 genes (one C4A and one
C4B), all leading to a deficient phenotype (Bak-Romaniszyn et al., 2011;
Kolho et al., 2015). This highlights the relevance of the complement
regulating properties of SALSA in this environment, and suggests an
additional mechanism for a detrimental outcome of expressing a func-
tionally impaired SALSA molecule.
SALSA is part of the mucosal inflammatory response. The protein
expression is induced by several factors that are altered in the local
environment of chronic inflammatory conditions, including IL-22,
NOD2 and TLR4 signalling. This may explain the observation of in-
creased SALSA levels in the affected mucosa. Normal SALSA functions
include both anti-microbial defence as well as interactions with the
epithelium. The latter includes a negative feedback mechanism on TLR4
signalling in response to microbial components. Despite the increased
expression of SALSA, certain isoforms with diminished anti-microbial
binding or faulty interaction with the epithelial negative feedback loop
could thus propagate mucosal inflammation and ultimately worsen IBD
(see Fig. 3).
6.2. SALSA and complement in cystic fibrosis
Cystic fibrosis (CF) is another example where a damaged mucosal
barrier leads to opportunistic pathogens infecting the host. CF is the
most commonly inherited genetic disease in persons of European des-
cent affecting 1 in 2500 newborns (Sallenave, 2014). The major
symptoms are observed in the lungs and digestive tract where cycles of
exocrine gland obstruction, infection and inflammation lead to de-
struction of the mucosal tissue (Rowe et al., 2005; Sallenave, 2014).
SALSA is upregulated in the pancreas and small intestine of the
CFTR knockout mouse indicating a possible protective role in this CF
model (De Lisle et al., 1998; De Lisle et al., 2001; Norkina et al., 2004).
A similar increased expression is observed for a number of complement
components in the epithelium and in mucosal secretions (Norkina et al.,
2004; Sass et al., 2015). The specific role of these anti-microbial mo-
lecules in the setting of CF is not clear. In the lung, a hallmark of CF is
colonization by Pseudomonas aeruginosa and S. aureus. While SALSA has
been shown to agglutinate S. aureus, no effect was observed on P. aer-
uginosa (Jumblatt et al., 2006). However, both microbes activate TLR4
signalling, and could thus lead to increased SALSA expression as de-
scribed in IBD. Interestingly, impaired monocyte phagocytosis of P.
aeruginosa was shown to be complement-dependent in CF (Van de
Weert-van Leeuwen et al., 2013). Currently no studies have addressed
the role of genetic variations in the SALSA molecule and the develop-
ment of CF. However, the functional relation between SALSA and dis-
ease would be interesting to address in the future.
The composition and viscosity of the mucus is a confounding factor
in the development of CF. Overexpression of a large glycoprotein, such
as SALSA, may affect the fluidity of the mucosal secretions directly. A
high amount of SALSA may thus lead to an exacerbated obstruction of
the luminal space, thus further propagating the pathogenesis (De Lisle
et al., 1998). Together with the inflammatory effects of SALSA, the
biochemical properties of the molecule could thus be detrimental to
disease progression in CF patients.
Fig. 2. Functions of SALSA at the mucosal surfaces
exemplified by the gut.
(I) SALSA is produced by epithelial cells as well as
various serous cells lining the glands and crypts of
the mucosa. SALSA is secreted both to the basal and
apical membranes of most mucosal epithelial cells.
Strong expression is observed in the developing
epithelium and the crypts of the small intestine. (II)
The SALSA molecule binds a number of micro-
organisms, and while associated to the epithelial
surface this may lead to increased transcytosis of
certain microbes. (III) In the fluid phase SALSA ag-
glutinates microbes, keeping them from colonizing
the mucosal epithelium. This scavenging function is
carried out in cooperation with endogenous ligands
of SALSA, such as IgA, SP-A, SP-D and lactoferrin.
(IV) In the case of epithelial damage mucosal com-
ponents may mix with tissue cells and proteins.
SALSA may then interact with complement mole-
cules such as C1q, MBL and the ficolins to regulate
complement activation.
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7. SALSA in non-mucosal tissues
Although most research has focused on the expression of SALSA at
the mucosal surfaces, new data is accumulating describing the expres-
sion of the protein also in the parenteral tissues. The expression of
SALSA has been described in the heart, liver, skin, tonsils and placenta
(Mollenhauer et al., 2001; Muller et al., 2009; Reichhardt et al., 2016).
In the heart tissue sporadic SALSA expression was found both in the
myocytes and in the endothelial cells (Muller et al., 2009, 2013). Fur-
thermore, we recently found SALSA expressed in the maternal decidual
endothelium during the first trimester of pregnancy. At term SALSA was
found intracellularly in the placental syncytiotrophoblast layer and in
distinct extracellular formations called fibrinoids (Reichhardt et al.,
2016). The expression of SALSA in both heart and placenta was scat-
tered, suggesting that the expression is inducible, rather than con-
stitutive. In the heart valves of patients with endocarditis the expression
of SALSA was increased specifically in the areas of infected valves in
association with colonizing bacteria (Muller et al., 2009). A similar
local up-regulation was observed in areas of amyloid deposits in pa-
tients suffering from cardiac amyloidosis (Muller et al., 2013). The
epithelial cells of the biliary duct have been found to express SALSA,
albeit weakly. However, under certain pathological conditions such as
hepatolithiasis the expression was induced (Sasaki et al., 2002).
It appears that danger signals and possibly certain inflammatory or
immunological stimuli may induce SALSA expression in tissues as well
as in the mucosal epithelium. A recent study showed that SALSA de-
posits into the extracellular matrix of vascular endothelium and affects
the proliferation, angiogenesis and vascular repair (Muller et al., 2012).
Placental angiogenesis is an ongoing process in the first trimester pla-
centa. Failure of angiogenesis leads to hypoxia and is a key feature of
several pregnancy complications (Jauniaux et al., 2000, 2003). For the
local capillaries and vessels this presents a “danger signal” for which a
response could be the expression of SALSA. This hypothesis corresponds
well to results from a mouse study where SALSA was found to be an
important ECM protein involved in both endothelial cell adhesion,
migration, proliferation and reparative angiogenesis (Muller et al.,
2012). Furthermore, it was shown that SALSA knock-out mice showed
an impaired recovery from ischemic hind-limb injury suggesting that
SALSA is involved in the process of endothelial cell response to hypoxia
(Muller et al., 2012).
To this date, SALSA has not been shown as a soluble protein in blood
plasma. Rather, it appears, that the molecule is immediately scavenged,
and kept from being free in blood, e.g. by deposition into the en-
dothelial ECM (Muller et al., 2012; Reichhardt et al., 2016). However,
the recent descriptions of SALSA expression in non-mucosal tissues,
such as heart and placenta, immediately puts the SALSA molecule into
an environment, where it could interact with complement components
directly following expression (Muller et al., 2009; Reichhardt et al.,
2016). SALSA deposition has been found to be associated with fibrin-
rich formations in both placental and heart tissue (Muller et al., 2009;
Reichhardt et al., 2016). We recently described partial co-localization
of SALSA and C1q in fibrinoid formations of the human placenta
(Reichhardt et al., 2016). In contrast, no co-localization was found
between SALSA and complement in the heart tissue (Muller et al.,
2013). Although not all SALSA expression was co-localized with com-
plement components, the interaction observed in the placenta is the
first evidence that SALSA and complement interact in vivo (Reichhardt
et al., 2016). Understanding the physiological outcome of the SALSA-
complement interactions, both on the mucosal surfaces and in the
parenteral tissues is an exciting issue for future research.
8. SALSA – a central player in the mucosal immunological
network?
Above we have described how SALSA interacts with the epithelial
cell surface, a multitude of bacterial and viral invaders, endothelial
cells, complement proteins, IgA and several other innate immune de-
fence molecules. Differently expressed isoforms of SALSA may have
stronger affinity for some molecules rather than others, making some
interactions more relevant than others in a biological setting. Yet the
prospect remains that SALSA is a molecule with an ability to influence
many types of cellular interactions and innate immunity. As such, it is
not surprising that the range of described involvement in both biolo-
gical processes and diseases is continuously expanding.
The overall function of SALSA at the mucosal surfaces appears clear.
The molecule agglutinates and removes invading micro-organisms,
while dampening the general inflammatory response. Simultaneously,
it maintains the integrity of the mucosal surface barrier by supporting
the homeostasis of the epithelial layer (Ligtenberg et al., 2010; Madsen
et al., 2010). Yet, the many versions of the SALSA molecule expressed,
Fig. 3. SALSA expression in inflamed epithelium.
The chronic inflammatory setting of Crohn’s disease
is associated with increased levels of the pro-in-
flammatory cytokines TNF- α, IL-22 and IL-27. These
cytokines activate signalling pathways in the epi-
thelial cells and through STAT3, NFκB, CREB and
ATF-2 stimulate the expression of SALSA. Once se-
creted, SALSA agglutinates and clears microbes,
leading to a decreased activation of TLR4 and NOD2
signalling. A SNP in the promoter region of SALSA
leads to diminished SALSA expression. Other muta-
tions lead to the expression of certain deletion var-
iants of SALSA, lacking several SRCR domains. Both
types of mutations diminish the function of SALSA,
and both types of mutations have been associated
with Crohn’s disease. It would appear, that the lack
of negative feedback on the TLR4/NOD2 signalling is
a likely mechanism by which a lack of functional
SALSA may exacerbate inflammation at the mucosal
surface, and thus propagate the development of
Crohn’s disease.
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and the multiple interactions it partakes in, also mean that it is a can-
didate for dysfunction in disease. This is particularly possible with
certain isoforms that have been linked to an exacerbated im-
munological response, as seen in Crohn’s disease. We are only begin-
ning to understand the multiple forms the protein presents in. Likewise,
we are only beginning to understand the impact on the mucosal im-
munity of the individual. Most of the effort’s in relation to SALSA re-
search have focused on diseases related to the intestines, but SALSA
may play equally important roles in diseases like cystic fibrosis and
even asthma. Future research may show us how this molecule may both
be important for increasing the effectiveness of immune responses, as
well as limiting damaging inflammatory processes and combatting in-
fections. In a society where chronic inflammatory conditions are on the
rise, a future knowledge of the complex interactions of SALSA may
prove to be essential.
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